PharmaCyte Biotech Inc PMCB Fundamentals and Key Ratios

PharmaCyte Biotech Inc. (PMCB) Fundamentals


PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

SHARE INFORMATION
Market Cap	$ 50,236,949
Shares Outstanding	17,443,385
Float	20,667,345
Percent Float	118.48%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 0
Latest Fiscal EPS	$ -0.80
Latest Fiscal Date	2022-04-30

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	4
Institutional Holdings Date	2021-08-31
Institutional Bought Previous 3 Months	57
Institutional Holdings Percent	0.0%
Institutional Sold Previous 3 Months	-
Insider Holdings Date	2023-02-28
Insider Bought Previous 3 Months	250,000
Insider Holdings Percent	3.4
Insider Sold Previous 3 Months	-
Insider Shares Owned	639,400

TRADING INFO
52 Week High	$ 3.10
52 Week Low	$ 1.85
52 Week High Change	$ 21.52
21 Day Moving Average	$ 2.9313
21 Day Extended Moving Average	$ 2.9177
50 Day Moving Average	$ 2.946
50 Day Extended Moving Average	$ 2.9295
200 Day Moving Average	$ 2.7143
200 Day Extended Moving Average	$ 3.0952
10 Day Average Volume	45,240
20 Day Average Volume	38,398
30 Day Average Volume	39,317
50 Day Average Volume	54,933
Alpha	-0.012435
Beta	-0.0179
Standard Deviation	0.313353
R2	0.000009
7 Day Price Change	$ 0.03
7 Day Percent Change	1.05%
21 Day Price Change	$ -0.09
21 Day Percent Change	-3.03%
30 Day Price Change	$ -0.08
30 Day Percent Change	-2.7%
Month to Date Price Change	$ -0.12
Month to Date Percent Change	-4.0%
Quarter to Date Price Change	$ -0.05
Quarter to Date Percent Change	-1.71%
180 Day Price Change	$ 0.305
180 Day Percent Change	11.84%
200 Day Price Change	$ 0.28
200 Day Percent Change	10.77%
Year to Date Price Change	$ -0.05
Year to Date Percent Change	-1.71%

PROFITABILITY
EBIT Margin	0.0%
EBITDA Margin	0.0%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	0.70
Total Debt To Equity	0.00
Int Coverage	-113,302.70
Current Ratio	88.00
Leverage Ratio	1.00
Quick Ratio	87.70
Long Term Debt To Capital	0.00

VALUATION MEASURES
PE Ratio	9.60
Enterprise Value	$ -22,577,704
Price to Sales	0.00
Price to Free Cash	-10.70
PE High Last 5 Years	-9.50
Price To Book	0.70
Price To Cash Flow	0.00
PE Low Last 5 Years	-6.30
Price to Tangible Book	0.70

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-6.73
Return on Equity	-6.78
Return on Capital	-8.21

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	Armanino LLP
CEO	Joshua Nathaniel Silverman
Emplyoees	4
Last Audit	UQ
CIK	0001157075
Industry	Biotechnology
Sector	Healthcare
NAICS	Research and Development in Biotechnology (except Nanobiotechnology)(541714)

CONTACT INFO
Address	3960 Howard Hughes Parkway Suite 500 Las Vegas, NV 89169
Website	https://www.pharmacyte.com
Facsimile	+1 917 595-2851
Telephone	+1 917 595-2850
Email	info@PharmaCyteBiotech.com

Boards:

Quotes:

PMCB

PharmaCyte Biotech Inc. (PMCB) Fundamentals

PharmaCyte Biotech Inc. (PMCB) Key Ratios

PharmaCyte Biotech Inc. (PMCB) Profile